Meet the Platform & Manufacturing Technologies team
Supporting the growth of breakthrough technology – Hubrecht Organoid Technology (HUB)
HUB is a not-for-profit Dutch company which has developed a paradigm-shifting platform for drug discovery and development, companion diagnostics and clinical patient stratification. HUB commercialises the pioneering work of Prof. Dr. Hans Clevers who developed methods to grow stem cell-derived tissue to provide organoids. Carpmaels & Ransford has been working closely with HUB for over ten years, providing the full spectrum of IP services, from the conception and global protection of the technology, through to licensing deals, trade mark applications and navigation around competitor activities. The Carpmaels & Ransford team has grown alongside HUB and has provided legal support and creative thinking to help launch this new platform technology into the wider research and clinical community.